Dr. Reddy's Laboratories (DRRD IN): Q3FY25 Result- Subdued US Business Dents Margin; Somber Outlook
Dr. Reddy's Laboratories reports stagnant US revenue in Q3FY25, dragged by lower contribution from Lenalidomide. Lack of growth catalysts...
207 Views
Dr Reddy's - Operationally in Line; Gross Margin Weakness a Clear Negative
Adjusted for multiple one-offs, Dr Reddy’s’ 2QFY25 PAT was in line with our and street estimates. EBITDA was marginally ahead, aided by a sales...
141 Views
Dr Reddy’s Laboratories - Decent Print; Work on Growth Levers Underway
Dr. Reddy’s Laboratories’ (DRL) Q2FY25 performance, adjusted for acquisition-related expenses (INR 561mn) and impairment charge of gNuvaring (INR...
122 Views
Dr Reddy’s Labs - North America/Russia/ROW Drive Earnings
DRRD exhibited robust YoY growth in North America (NA), Russia, and ROW markets and a healthy scale-up in the pharmaceutical services and active...
122 Views
Dr. Reddy’s Laboratories Ltd - Potential Investments & Pipelines to Unlock Value
Reported revenue grew by 16.5% YoY, driven by strong growth in the North America business (18% YoY) and India business (18% YoY). The Europe...
156 Views